Innovent Biologics, Inc. (IVBIY)

Market Cap	18.71B
Revenue (ttm)	1.29B
Net Income (ttm)	-12.96M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	284.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117
Average Volume	341
Open	39.31
Previous Close	n/a
Day's Range	39.31 - 39.31
52-Week Range	19.15 - 45.72
Beta	0.23
RSI	66.51
Earnings Date	Aug 22, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: OTCMKTS
• Ticker Symbol: IVBIY

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY